TY  - JOUR
AU  - Entrenas Costa, Luis Manuel
AU  - Casas-Maldonado, Francisco
AU  - Soto Campos, José Gregorio
AU  - Padilla-Galo, Alicia
AU  - Levy, Alberto
AU  - Álvarez Gutiérrez, Francisco Javier
AU  - Gómez-Bastero Fernández, Ana P
AU  - Morales-García, Concepción
AU  - Gallego Domínguez, Rocío
AU  - Villegas Sánchez, Gustavo
AU  - Mateos Caballero, Luis
AU  - Pereira-Vega, Antonio
AU  - García Polo, Cayo
AU  - Pérez Chica, Gerardo
AU  - Martín Villasclaras, Juan José
PY  - 2019
DO  - 10.1007/s41669-019-0117-4
UR  - https://hdl.handle.net/10668/25494
T2  - PharmacoEconomics - open
AB  - Omalizumab is a fully humanized monoclonal antibody indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma. The aim of this study was to evaluate social, healthcare expenditure and clinical outcomes...
LA  - en
TI  - Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study.
TY  - research article
VL  - 3
ER  -